 This is a Phase 2b, randomized, double-blind, parallel-group, placebo-controlled, multicenter study investigating the safety, tolerability and efficacy of two oral doses of GS-9450 in adults with chronic Hepatitis C Virus HCV. Approximately 240 subjects 18-65 years of age who meet study entry criteria will be randomized in other words, selected at random, like flipping a coin to one of three treatment groups 80 subjects per treatment group as follows:GS-9450 10 mg once daily,GS-9450 40 mg once daily, or matching placebo once daily. 